Rituximab-Treatment of an Antibody Mediated Rejection 9 Years after Bilateral Forearm Transplantation

Annemarie Wei├čenbacher, Theresa Hautz, Bernhard Zelger, Bettina Zelger, Dolores Wolfram-Raunicher, Robert Sucher, Raimund Margreiter, Gerald Brandacher, Johann Pratschke & Stefan Schneeberger
Introduction: Clinical relevance of antibody-mediated rejection (AMR) in vascularized composite allotransplantation (VCA) has not been defined. While C4d deposition and DSAs have been previously described in hand and face transplant recipients, no clinical relevance has been reported. We herein describe[for full text, please go to the a.m. URL]